Lakewood-Amedex Biotherapeutics (LABT) Registration filing summary

Company overview and business model

• Focuses on developing novel antimicrobial therapeutics, particularly the Bisphosphocin® class, to address critical unmet needs in infectious diseases driven by antimicrobial resistance (AMR).

• Lead product candidate, Nu-3, is a topical gel for infected diabetic foot ulcers (iDFU), with additional pipeline compounds targeting urinary tract and pulmonary infections.

• Holds 68 issued and 36 pending patents covering core technologies and product candidates in major pharmaceutical markets.

• Employs an outsourced manufacturing model using third-party CDMOs for clinical and future commercial supply.

• Business strategy centers on advancing Nu-3 through clinical trials and expanding the Bisphosphocin® platform to other high-need indications.

Financial performance and metrics

• Reported net losses of $3.8 million in 2025 and $4.8 million in 2024, with an accumulated deficit of $53.4 million as of December 31, 2025.

• Operating expenses in 2025 were $3.8 million, primarily for R&D ($1.3 million) and G&A ($2.5 million).

• Cash and cash equivalents were $0.2 million at year-end 2025, with a working capital deficit of $2.1 million.

• Raised $46.1 million in gross proceeds since inception through equity and convertible debt financings.

• Auditors expressed substantial doubt about the company’s ability to continue as a going concern.

Use of proceeds and capital allocation

• Will not receive proceeds from the resale of registered shares by stockholders in the direct listing.

• Proceeds from a concurrent $7.5 million Series C Preferred Stock private placement are intended to fund completion of the Phase 2a Nu-3 clinical trial.

• Additional capital will be required to advance clinical programs, expand the pipeline, and support commercialization.